Cannabinoid Encyclopedia

Focused research review

What do we know about THCV safety?

What evidence connects THCV with safety, tolerability, adverse-event, impairment, or formulation-specific outcomes?

Updated July 2026 24 research sources Human and early research

The short answer

What is the bottom line?

Research has examined THCV safety. This page brings together 6 human-study sources, 7 research reviews, and 5 lab, animal, or mechanism sources. The source set includes human research as well as earlier-stage studies. The studies do not all test the same product, dose, group of people, or outcome, so they cannot be reduced to one answer for every person or product. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about THCV safety.

What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Key takeaways

What to know first

  1. 1

    Research on THCV safety covers Safety, tolerability, adverse-event, impairment, THC-interaction, or formulat...; those areas should not be combined into one claim. 1

  2. 2

    The source set includes human research as well as earlier-stage studies. 2

  3. 3

    Dose, formulation, route, study population, and outcome can change how closely a study applies to a real-world question. 3

Research areas

What researchers studied about THCV safety

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Too limited for a firm answer

Safety, tolerability, adverse-event, impairment, THC-interaction, or formulat...

This part of the literature focuses on Safety, tolerability, adverse-event, impairment, THC-interaction, or formulat.... Studies may use different compounds, formulations, doses, routes, groups of people, and outcomes, so the details of each source matter. 2

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

6 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

7 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

5 sources

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

Another 6 of 24 research sources could not be placed cleanly into those three groups from the recorded study details.

What these studies actually looked at

The research on THCV safety is not one kind of study. This source set includes 7 narrative or expert reviews, 5 animal studies, 4 clinical studies in people, and 1 case report or case series. 3

The recorded populations or models include people or patients (8 sources), animal models (5 sources), and cells or tissue models (2 sources). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns (24 sources). Closely related outcome names can still describe different measurements. 5

The THCV safety source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

narrative or expert review

Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review.

On this page, this source examines THCV and safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns. 1

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns
Evidence stage
evidence still limited

narrative or expert review

The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management.

On this page, this source examines THCV and safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns. 2

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns
Evidence stage
evidence still limited

clinical study in people

Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study.

On this page, this source examines THCV and safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns. 3

Study type
clinical study in people
Population or model
people or patients
Outcome focus
safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns
Evidence stage
mechanism-focused research

animal study

Toxicological Evaluation and Pain Assessment of Four Minor Cannabinoids Following 14-Day Oral Administration in Rats.

On this page, this source examines THCV and safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns. 4

Study type
animal study
Population or model
animal models
Outcome focus
safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns
Evidence stage
preclinical research

clinical study in people

A Two-Phase, Dose-Ranging, Placebo-Controlled Study of the Safety and Preliminary Test of Acute Effects of Oral Δ8-Tetrahydrocannabivarin in Healthy Participants.

On this page, this source examines THCV and safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns. 5

Study type
clinical study in people
Population or model
people or patients
Outcome focus
safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns
Evidence stage
human research

Safety and limits

What should readers keep in mind?

Research on THCV safety should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 2

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

What evidence connects THCV with safety, tolerability, adverse-event, impairment, or formulation-specific outcomes?

Relevant research is collected here. The source set includes human research as well as earlier-stage studies. 7

Why is there not always a yes-or-no answer?

The sources may test different products, doses, people, and outcomes, so a single conclusion can hide important differences. 8

Where can I read the original studies?

Use the numbered citations and the source list at the bottom of the page to open PubMed or DOI records. 9

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review. narrative or expert review; evidence still limited PubMed 37630401 DOI 10.3390/molecules28166149
  2. 2
    The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management. narrative or expert review; evidence still limited PubMed 40270953 DOI 10.3934/neuroscience.2025003
  3. 3
    Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. clinical study in people; mechanism-focused research PubMed 27573936 DOI 10.2337/dc16-0650
  4. 4
    Toxicological Evaluation and Pain Assessment of Four Minor Cannabinoids Following 14-Day Oral Administration in Rats. animal study; preclinical research PubMed 37721989 DOI 10.1089/can.2023.0049
  5. 5
    A Two-Phase, Dose-Ranging, Placebo-Controlled Study of the Safety and Preliminary Test of Acute Effects of Oral Δ8-Tetrahydrocannabivarin in Healthy Participants. clinical study in people; human research PubMed 37721990 DOI 10.1089/can.2023.0038
  6. 6
    Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers. clinical study in people; evidence still limited PubMed 25542687 DOI 10.1093/ijnp/pyu094
  7. 7
    The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. clinical study in people; mechanism-focused research PubMed 26577065 DOI 10.1177/0269881115615104
  8. 8
    Cannabinoids and terpenes for diabetes mellitus and its complications: from mechanisms to new therapies. narrative or expert review; evidence still limited PubMed 36280497 DOI 10.1016/j.tem.2022.08.003
  9. 9
    CB₁-independent mechanisms of Δ⁹-THCV, AM251 and SR141716 (rimonabant). narrative or expert review; evidence still limited PubMed 21740450 DOI 10.1111/j.1365-2710.2011.01284.x
  10. 10
    Investigational cannabinoids in seizure disorders, what have we learned thus far? narrative or expert review; evidence still limited PubMed 29842819 DOI 10.1080/13543784.2018.1482275
  11. 11
    Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management. narrative or expert review; evidence still limited PubMed 40872492 DOI 10.3390/ph18081101
  12. 12
    Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders. narrative or expert review; evidence still limited PubMed 31549358 DOI 10.1007/s40263-019-00664-w
See all 24 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management. narrative or expert review; evidence still limited / 1 linked research note PubMed 40270953
  2. Investigational cannabinoids in seizure disorders, what have we learned thus far? narrative or expert review; evidence still limited / 1 linked research note PubMed 29842819
  3. Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. clinical study in people; mechanism-focused research / 1 linked research note PubMed 27573936
  4. CB₁-independent mechanisms of Δ⁹-THCV, AM251 and SR141716 (rimonabant). narrative or expert review; evidence still limited / 1 linked research note PubMed 21740450
  5. SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 42196303
  6. Ultrafast, Selective, and Highly Sensitive Nonchromatographic Analysis of Fourteen Cannabinoids in Cannabis Extracts, Δ8-Tetrahydrocannabinol Synthetic Mixtures, and Edibles by Cyclic Ion Mobility Spectrometry-Mass Spectrometry. evidence still limited / 1 linked research note PubMed 38862388
  7. Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management. narrative or expert review; evidence still limited / 1 linked research note PubMed 40872492
  8. Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review. narrative or expert review; evidence still limited / 1 linked research note PubMed 37630401
  9. Toxicological Evaluation and Pain Assessment of Four Minor Cannabinoids Following 14-Day Oral Administration in Rats. animal study; preclinical research / 1 linked research note PubMed 37721989
  10. A Two-Phase, Dose-Ranging, Placebo-Controlled Study of the Safety and Preliminary Test of Acute Effects of Oral Δ8-Tetrahydrocannabivarin in Healthy Participants. clinical study in people; human research / 1 linked research note PubMed 37721990
  11. Effect of cannabinol, tetrahydrocannabivarin and cannabidiol on voluntary alcohol consumption. animal study; mechanism-focused research / 1 linked research note PubMed 41947574
  12. Effect of cannabidiol, cannabinol and tetrahydrocannabivarin in managing inflammatory pain. animal study; preclinical research / 1 linked research note PubMed 42151379
  13. Prevalence of ∆8-tetrahydrocannabinol carboxylic acid in workplace drug testing. evidence still limited / 1 linked research note PubMed 37697897
  14. Examining impairment and kinetic patterns associated with recent use of hemp-derived Δ8-tetrahydrocannabinol: case studies. evidence still limited / 1 linked research note PubMed 35799289
  15. Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers. clinical study in people; evidence still limited / 1 linked research note PubMed 25542687
  16. The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. clinical study in people; mechanism-focused research / 1 linked research note PubMed 26577065
  17. Hair Regrowth with Novel Hemp Extract: A Case Series. case report or case series; mechanism-focused research / 1 linked research note PubMed 37305187
  18. Differences in Online Descriptions and Marketing of Derived Intoxicating Cannabis Products. evidence still limited / 1 linked research note PubMed 40131178
  19. Role of Cannabidiol and Tetrahydrocannabivarin on Paclitaxel-induced neuropathic pain in rodents. animal study; evidence still limited / 1 linked research note PubMed 35303507
  20. The cannabinoid Δ(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity. animal study; mechanism-focused research / 1 linked research note PubMed 23712280
  21. Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders. narrative or expert review; evidence still limited / 1 linked research note PubMed 31549358
  22. Cannabinoids and terpenes for diabetes mellitus and its complications: from mechanisms to new therapies. narrative or expert review; evidence still limited / 1 linked research note PubMed 36280497
  23. Indeterminacy of cannabis impairment and ∆9-tetrahydrocannabinol (∆9-THC) levels in blood and breath. evidence still limited / 1 linked research note PubMed 35585089
  24. Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. evidence still limited / 1 linked research note PubMed 23894589